Bailard
ARCT icon

Bailard’s Arcturus Therapeutics ARCT Stock Holding History

Bailard’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-4,135
Closed -$447K – 234
2014
Q3 		$447K Sell
4,135
-865
-17% -$113K 0.07% 141
2014
Q2 		$606K Hold
5,000
– – 0.09% 114
2014
Q1 		$635K Buy
+5,000
New +$741K 0.1% 112

Other funds holding ARCT

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Bailard's ARCT Position: Q4 2014 in Review

Bailard sold out of Arcturus Therapeutics (ARCT) in Q4 2014, closing a stake of 4,135 shares — an estimated $447K sold.

Bailard first reported a position in ARCT in Q1 2014 and held it in 3 quarters. The position peaked at $635K in Q1 2014. 28 funds tracked by Wall St. Rank hold ARCT as of Q4 2014.

  • Bailard reported no remaining Arcturus Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Bailard sold 4,135 Arcturus Therapeutics shares in Q4 2014, an estimated $447K.
  • Bailard first reported a position in Arcturus Therapeutics in Q1 2014 and held it in 3 quarters.
  • Bailard's Arcturus Therapeutics position peaked at $635K in Q1 2014.
  • 28 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2014.

Based on Bailard's 13F filing for Q4 2014, filed 26 Jan 2015.